School of Biotechnology and Bioinformatics, D.Y. Patil Deemed to be University, CBD Belapur, Navi Mumbai 400614, India.
CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road, Pune 411 008, India.
J Struct Biol. 2022 Sep;214(3):107877. doi: 10.1016/j.jsb.2022.107877. Epub 2022 Jun 21.
Chemokine receptors are the central signaling hubs of several processes such as cell migration, chemotaxis and cell positioning. In this graphical review, we provide an overview of the structural and mechanistic principles governing chemokine recognition that are currently emerging. Structural models of chemokine-receptor co-complexes with endogenous chemokines, viral chemokines and therapeutics have been resolved that highlight multiple interaction sites, termed as CRS1, CRS1.5 etc. The first site of interaction has been shown to be the N-terminal domain of the receptors (CRS1 site). A large structural flexibility of the N-terminal domain has been reported that was supported by both experimental and simulation studies. Upon chemokine binding, the N-terminal domain appears to show constricted dynamics and opens up to interact with the chemokine via a large interface. The subsequent sites such as CRS1.5 and CRS2 sites have been structurally well resolved although differences arise such as the localization of the N-terminus of the ligand to a major or minor pocket of the orthosteric binding site. Several computational studies have highlighted the dynamic protein-protein interface at the CRS1 site that seemingly appears to resolve the differences in NMR and mutagenesis studies. Interestingly, the differential dynamics at the CRS1 site suggests a mixed model of binding with complex signatures of both conformational selection and induced fit models. Integrative experimental and computational approaches could help unravel the structural basis of promiscuity and specificity in chemokine-receptor binding and open up new avenues of therapeutic design.
趋化因子受体是细胞迁移、趋化和细胞定位等多个过程的核心信号枢纽。在这篇图形综述中,我们概述了目前新兴的趋化因子识别的结构和机制原则。已经解析了趋化因子-受体复合物与内源性趋化因子、病毒趋化因子和治疗药物的结构模型,这些模型突出了多个相互作用位点,称为 CRS1、CRS1.5 等。第一个相互作用位点已被证明是受体的 N 端结构域(CRS1 位点)。据报道,N 端结构域具有较大的结构灵活性,这得到了实验和模拟研究的支持。在趋化因子结合后,N 端结构域似乎表现出受限的动力学,并通过大的相互作用界面打开以与趋化因子相互作用。随后的位点,如 CRS1.5 和 CRS2 位点,结构上已经得到很好的解析,尽管存在差异,例如配体的 N 端定位到正位结合位点的主要或次要口袋。几项计算研究强调了 CRS1 位点的动态蛋白质-蛋白质界面,似乎解决了 NMR 和诱变研究中的差异。有趣的是,CRS1 位点的差异动力学表明,结合具有构象选择和诱导契合模型的复杂特征的混合模型。综合实验和计算方法可以帮助揭示趋化因子-受体结合的混杂性和特异性的结构基础,并为治疗设计开辟新途径。